Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

As COVID-19 threats to become endemic, a potential silver lining for pharma

By Brian Buntz | February 9, 2021

SARS CoV-2

[Image courtesy of Wikipedia]

Reality is beginning to sink in. Despite the availability of a growing number of COVID-19 vaccines and other therapies, the SARS-CoV-2 virus is likely to become endemic in the medium term, if not longer.

A handful of coronaviruses — among them strains of NL63, OC43, 229E and HKU1 — are already endemic.

For drug developers, an endemic SARS-CoV-2 could have significant implications. While effective COVID-19 vaccines will likely enable developed nations to roll back coronavirus-related restrictions, demand for new COVID-19 treatments and vaccines could remain elevated for years.

A crowded market with robust competition promises to translate to more success in battling the pandemic.

More than 300 COVID-19 therapies are now in development. This year alone, Moderna (NSDQ:MRNA) and Pfizer (NYSE:PFE) could rake in $32 billion in COVID-19 vaccine sales, according to Morgan Stanley.

The pandemic has already changed many people’s view of the pharmaceutical industry, according to Gilead Raday, COO at Redhill Biopharma (NSDQ:RDHL).

“It’s really realigning the thinking around the industry — certainly around fields such as infectious diseases, which have been somewhat neglected and minimized in the pharma industry,” Raday said.

The pandemic is also driving tighter collaboration between regulators, academic researchers and industry. “Without efficient collaboration between these three entities going forward, there is a big gap between what we want to achieve and what we can achieve,” Raday added. “There are still a lot of lessons being learned in terms of how to structure large studies, how to move quickly and allow innovation to thrive while still maintaining rigorous standards.”

As the virus continues to mutate, efforts to develop bespoke vaccines and therapies that remain effective against emerging variants will likely remain elevated.

As a growing number of therapies to prevent or minimize acute COVID-19 symptoms become available, demand could also increase for treatments to help patients manage long-term COVID-19 symptoms, which can include fatigue, insomnia, shortness of breath and loss of taste or smell.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: coronavirus, covid-19, COVID-19 vaccine, COVID-19 vaccine trial, infectious diseases, Pharmaceutical market
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50